BCRX: BioCryst Pharmaceuticals Inc

8.22 USD 0.03 (0.36%)

Secteur: Soins de Santé Base: US Dollar Devise de profit: US Dollar

Le taux de change de BCRX a changé de -0.36% aujourd'hui. Au cours de la journée, l'instrument a été échangé à un minimum de 8.12 et à un maximum de 8.39.

Suivez la dynamique BioCryst Pharmaceuticals Inc. Les cotations en temps réel vous aideront à réagir rapidement aux changements du marché. En basculant entre différentes périodes, vous pouvez surveiller les tendances et la dynamique des taux de change par minutes, heures, jours, semaines et mois. Utilisez ces informations pour prévoir les changements du marché et prendre des décisions de trading éclairées.

Graphique en Plein Ecran

BCRX Nouvelles

Zacks 14:00 Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
Zacks 14:00 BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth
Investing 17:32 BioCryst stock undervalued ahead of Q2 earnings, says RBC Capital
Investing 17:20 Citizens JMP downgrades Clearside Biomedical stock rating as company pauses R&D
Investing 11:46 Clearside Biomedical stock falls after announcing strategic alternatives exploration
Seeking Alpha 19:24 Astria: Betting On Navenibart In The Crowded HAE Arena
Investing 11:05 BioCryst Pharmaceuticals appoints Babar Ghias as CFO
Benzinga 14:41 BioCryst Just Ditched Its Europe Business — Here's Why Investors Are Cheering - BioCryst Pharma (NASDAQ:BCRX)
Investing 12:19 BioCryst stock rises after $264 million sale of European ORLADEYO business
Investing 11:04 BioCryst to sell European ORLADEYO business to Neopharmed for $264M
Investing 11:04 FDA extends review period for BioCryst pediatric drug application to December
Investing 11:09 BioCryst reports long-term efficacy of ORLADEYO in HAE treatment
Investing 11:06 Colombia approves BioCryst’s oral HAE treatment ORLADEYO
Investing 14:15 BioCryst at Goldman Sachs Conference: Strategic Growth and Profitability
Seeking Alpha 21:26 Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside
Investing 11:05 Netherlands approves BioCryst’s HAE drug ORLADEYO for reimbursement
Investing 11:36 biocryst pharmaceuticals extends cfo consulting agreement
Investing 11:32 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Investing 11:32 BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
Investing 11:06 BioCryst reports efficacy of HAE drug across age groups
Investing 13:44 Cantor Fitzgerald maintains overweight on Metsera shares
Investing 11:28 BioCryst to Present at Upcoming Investor Conferences
Investing 11:05 BioCryst reports ORLADEYO reduces severe HAE attack rates
Benzinga 21:29 BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors - BioCryst Pharma (NASDAQ:BCRX)

Range quotidien

8.12 8.39

Range Annuel

6.01 11.31

Clôture Précédente: 8.09
Ouverture: 8.25

Bid: 8.22
Ask: 8.52

Plus Bas: 8.12
Plus Haut: 8.39

Volume: 5.803 K

Changement quotidien: -0.36%
Changement Mensuel: -8.46%

Changement à 6 Mois: 6.48%
Changement Annuel: 12.60%

30 juillet, mercredi